Cargando…

Challenges in the discontinuation of chronic hepatitis B antiviral agents

Long-term antiviral treatment of chronic hepatitis B patients has been proven to be beneficial in reducing liver-related complications. However, lengthy periods of daily administration of medication have some inevitable drawbacks, including decreased medication adherence, increased cost of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaewdech, Apichat, Sripongpun, Pimsiri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473499/ https://www.ncbi.nlm.nih.gov/pubmed/34630873 http://dx.doi.org/10.4254/wjh.v13.i9.1042

Ejemplares similares

Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Phlegmonous Proctitis: A Rare Entity of the Presentation of Proctitis
por: Kaewdech, Apichat, et al.
Publicado: (2018)

Discontinuation of antiviral therapy in chronic hepatitis B patients
por: Medas, Renato, et al.
Publicado: (2021)

Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update
por: Sripongpun, Pimsiri, et al.
Publicado: (2022)

Amoxycillin-Clavulanic Acid-Induced Esophageal Ulcer: An Unusual Cause
por: Kaewdech, Apichat, et al.
Publicado: (2020)

The effect of fiber supplementation on the prevention of diarrhea in hospitalized patients receiving enteral nutrition: A meta-analysis of randomized controlled trials with the GRADE assessment
por: Kaewdech, Apichat, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
por: Kaewdech, Apichat, et al.
Publicado: (2022)

The efficacy of branched-chain amino acid granules to restore phagocytic activity in cirrhosis patients, a randomized controlled trial
por: Chamroonkul, Naichaya, et al.
Publicado: (2023)

HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program
por: Sono, Supinya, et al.
Publicado: (2022)

Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients
por: Kaewdech, Apichat, et al.
Publicado: (2021)

The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study
por: Kaewdech, Apichat, et al.
Publicado: (2022)

ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization
por: Bannangkoon, Kittipitch, et al.
Publicado: (2021)

Utility of handgrip strength (HGS) and bioelectrical impedance analysis (BIA) in the diagnosis of sarcopenia in cirrhotic patients
por: Luengpradidgun, Lalida, et al.
Publicado: (2022)

FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE
por: Kaewdech, Apichat, et al.
Publicado: (2023)

Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
por: Wu, Ya-Li, et al.
Publicado: (2019)

Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
por: Sripongpun, Pimsiri, et al.
Publicado: (2023)

Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease
por: Khoo, Tiffany, et al.
Publicado: (2021)

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
por: Liu, Ya-Yun, et al.
Publicado: (2018)

Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018)

Diagnostic performance of endoscopic ultrasound-guided tissue acquisition by EUS-FNA versus EUS-FNB for solid pancreatic mass without ROSE: a retrospective study
por: Wong, Thanawin, et al.
Publicado: (2022)

Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA
por: Zhou, Jing, et al.
Publicado: (2022)

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched
por: Compagnoni, Stella, et al.
Publicado: (2021)

Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
por: Kamal, Ahmed, et al.
Publicado: (2022)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
por: Stuckey, Ruth, et al.
Publicado: (2020)

HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication
por: Praneenararat, Surat, et al.
Publicado: (2014)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
por: Said, Zeinab Nabil Ahmed, et al.
Publicado: (2022)

Value and risk of percutaneous liver biopsy in patients with cirrhosis and clinical suspicion of autoimmune hepatitis
por: Sripongpun, Pimsiri, et al.
Publicado: (2021)

Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals
por: Baumert, Thomas F., et al.
Publicado: (2017)

Kidney transplant from donors with hepatitis B: A challenging treatment option
por: Srisuwarn, Praopilad, et al.
Publicado: (2021)

Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases
por: Kawanaka, Miwa, et al.
Publicado: (2021)

Chronic hepatitis B in pregnant women: Current trends and approaches
por: Belopolskaya, Maria, et al.
Publicado: (2021)

Chronic hepatitis B: New potential therapeutic drugs target
por: Leowattana, Wattana, et al.
Publicado: (2022)

Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
por: Guo, Jiang, et al.
Publicado: (2021)

Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients
por: Lee, Hye Won, et al.
Publicado: (2016)

Small changes, big results: evolution of morphological discontinuity in mammals
por: Honeycutt, Rodney L
Publicado: (2008)

Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA
por: Sekiba, Kazuma, et al.
Publicado: (2018)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_udlq1ghd12kbfc150e4j3c369v